Abstract Background Favipiravir and Molnupiravir, orally available antivirals, have been
reported to exert antiviral activity against SARS-CoV-2. First efficacy data have been recently …

Rapid changes in the viral genome allow viruses to evade threats posed by the host immune
response or antiviral drugs, and can lead to viral persistence in the host cells. RNA …

Background: Whether hospitalized patients benefit from COVID-19 oral antivirals is
uncertain. Objective: To examine the real-world effectiveness of molnupiravir and …

Background: Randomized trial evidence suggests that some antiviral drugs are effective in
patients with COVID-19. However, the comparative effectiveness of antiviral drugs in …

Objective To compare the effects of treatments for coronavirus disease 2019 (covid-19).
Design Living systematic review and network meta-analysis. Data sources WHO covid-19 …

Background Oral drugs against severe acute respiratory syndrome coronavirus 2 (SARS-
CoV-2) have received emergency use authorization for the treatment of mild-to-moderate …

A recently published article described the safety, tolerability, and pharmacokinetic profile of
molnupiravir (Painter et al. 2021), a novel antiviral agent with potent activity against severe …